Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: mendelian randomization study
Open Access
- 14 September 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1240754
Abstract
Background: The interleukin-1 pathway has been linked to pancreatic diseases. We applied the Mendelian randomization approach to explore whether higher interleukin-1 receptor antagonist (IL-1RA) levels reduce the risk of acute and chronic pancreatitis and pancreatic cancer.Methods: Genetic variants associated with blood IL-1RA levels at the genome-wide significance level and located 5MB downstream or upstream of the IL1RN gene were extracted from a genome-wide meta-analysis of 21,758 participants. After pruning, genetic variants without linkage disequilibrium were used as genetic instrument for IL-1RA. Summary-level data on acute and chronic pancreatitis and pancreatic cancer were obtained from the UK Biobank and FinnGen studies. The associations were meta-analyzed for one outcome from two sources.Results: Genetically predicted higher levels of IL-1RA were associated with a lower risk of acute and chronic pancreatitis and pancreatic cancer. In the meta-analysis of UK Biobank and FinnGen, the combined odds ratio was 0.87 (95% confidence interval [CI] 0.77-0.97, P=0.003) for acute pancreatitis, 0.73 (95% CI 0.65-0.82, P=2.93×10-8) for chronic pancreatitis, and 0.86 (95% CI 0.77-0.96, P=0.009) for pancreatic cancer per one standard deviation increment in genetically predicted levels of IL-1RA.Conclusion: This study suggests a protective role of IL-1RA in three major pancreatic diseases, which hints the therapeutic potentials of IL-1RA in pancreatic diseases.Keywords
This publication has 36 references indexed in Scilit:
- Genetics of rheumatoid arthritis contributes to biology and drug discoveryNature, 2013
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) attenuates caerulein-induced chronic pancreatitis in miceBiomedicine & Pharmacotherapy, 2012
- Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetesNature Reviews Drug Discovery, 2011
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals of the Rheumatic Diseases, 2011
- Cyst Fluid Interleukin-1β (IL1β) Levels Predict the Risk of Carcinoma in Intraductal Papillary Mucinous Neoplasms of the PancreasClinical Cancer Research, 2011
- Anakinra for rheumatoid arthritisCochrane Database of Systematic Reviews, 2009
- Overexpression of Interleukin-1β in the Murine Pancreas Results in Chronic PancreatitisGastroenterology, 2008
- Interleukin-1–Receptor Antagonist in Type 2 Diabetes MellitusNew England Journal of Medicine, 2007
- Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytesDiabetologia, 2006